V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20216468 | 20134956 | 1.8 | 64 | Palliative (P) | 2016-08-14 | 2016-08-15 | Gemcitabine + Oxaliplatin | 02 | N | AFLIBERCEPT + FLUOROURACIL + IRINOTECAN | 101853436 |
| 20216504 | 20134957 | 1.83 | 84.25 | 03 | 2018-09-24 | 2018-09-24 | BCG Intravesical | N | N | CISPLATIN + FLUOROURACIL + STREPTOZOCIN | 100155579 |
| 20216542 | 20134958 | 1.69 | 64 | null | 2019-01-03 | 2019-01-15 | ECF | 02 | N | CARBOPLATIN + RALTITREXED | 100867680 |
| 20216564 | 20134959 | 1.73 | 55.3 | null | 2018-08-28 | 2018-10-02 | Cisplatin + Radiotherapy + CISPLATIN | 02 | null | BACILLUS CALMETTE-GUERIN | 100380810 |
| 20216702 | 20134960 | 1.82 | 0 | Palliative (P) | 2020-01-06 | 2020-01-11 | Apalutamide | 02 | null | CETUXIMAB + CISPLATIN + FLUOROURACIL | 100102701 |
| 20216786 | 20134961 | 1.58 | 50 | Curative (C) | 2017-10-24 | 2017-10-29 | Cape+Cetuximab+Oxalip (2 wk) Maint | 02 | N | STS NON-RHABDO EPSSG 2005 IVA | 101392092 |
| 20216833 | 20134962 | 1.6 | 106.5 | null | 2018-12-14 | 2018-12-20 | null | 02 | null | FLAG | 101529017 |
| 20216940 | 20134964 | 1.79 | 90.4 | Palliative (P) | 2017-12-10 | 2018-01-31 | Cisplatin + Vinorelbine (IV) | 02 | N | RITUXIMAB | 100238300 |
| 20217055 | 20134965 | 1.75 | 48.4 | Adjuvant (A) | 2018-03-22 | 2018-04-05 | SCOPE 1 TRIAL | 02 | null | ERIBULIN | 101175464 |
| 20217138 | 20134967 | 1.5 | 90.28 | Adjuvant (A) | 2018-09-05 | 2018-12-19 | Bevacizumab + Capecitabine | N | N | CISPLATIN + FLUOROURACIL + RT | 100026444 |
| 20217208 | 20134968 | 1.71 | 51.7 | 03 | 2017-05-21 | 2017-05-21 | null | 2 | N | CISPLATIN + GEMCITABINE + RITUXIMAB | 100203488 |
| 20217411 | 20134970 | 1.75 | 89.4 | Curative (C) | 2017-09-13 | 2017-12-17 | EC | 01 | N | CAV | 101264157 |
| 20217473 | 20134971 | 0 | 93 | 03 | 2019-06-30 | 2019-07-13 | EC | 02 | N | TRANSPLANT CAR-T CELLS - AXICABTAGENE CILOLEUCEL | 101055865 |
| 20217550 | 20134972 | 1.81 | 25.5 | Curative (C) | 2019-08-13 | 2019-08-25 | Bendamustine + Obinutuzumab | N | N | CISPLATIN + RT | 101585541 |
| 20217603 | 20134973 | 1.84 | 115.9 | null | 2018-11-29 | 2018-12-01 | Bevacizumab + Oxaliplatin +MdG | 01 | null | CISPLATIN + FLUOROURACIL + RT | 101362530 |
| 20217723 | 20134974 | 1.81 | 61.95 | Neo-adjuvant (N) | 2020-06-09 | 2020-06-09 | CAP + RT | 02 | null | CARBOPLATIN + RT | 100683398 |
| 20217738 | 20134975 | 1.8 | 115.9 | null | 2017-03-11 | 2017-03-23 | DABRAFENIB + TRAMETINIB | null | null | CISPLATIN + FLUOROURACIL + RT | 101110137 |
| 20218089 | 20134977 | 0.94 | 87 | Neo-adjuvant (N) | 2019-09-13 | 2019-09-21 | AFLIBERCEPT + FLUOROURACIL + IRINOTECAN | 02 | N | BINIMETINIB + ENCORAFENIB | 100872689 |
| 20218123 | 20134978 | 1.77 | 58.8 | null | 2020-01-17 | 2020-01-25 | ECarboX | 02 | N | MITOMYCIN | 100937178 |
| 20218158 | 20134979 | 1.57 | 56.4 | Curative (C) | 2020-07-09 | 2020-08-12 | FLUOROURACIL + Panitumumab | 01 | N | IVA | 100994352 |
| 20218161 | 20134980 | 1.72 | 56.7 | Curative (C) | 2019-06-12 | 2019-06-19 | IDARUBICIN + TRETINOIN | 02 | N | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | 100382991 |
| 20218537 | 20134982 | 1.84 | 66 | Adjuvant (A) | 2019-06-18 | 2019-06-20 | CISPLATIN + TEYSUNO | 01 | null | LETROZOLE + PALBOCICLIB | 100656898 |
| 20218548 | 20134983 | 1.72 | 50 | null | null | 2021-04-18 | CISPLATIN + VINORELBINE | Y | null | ISATUXIMAB + POMALIDOMIDE | 101591771 |
| 20218589 | 20134984 | 1.65 | 67.1 | Curative (C) | 2021-12-20 | 2021-12-23 | SCOPE 2 TRIAL | 02 | null | ERIBULIN | 100302031 |
| 20218603 | 20134985 | 1.54 | 59 | 03 | 2018-03-27 | 2018-05-06 | DABRAFENIB + TRAMETINIB | 2 | N | BEVACIZUMAB + CAPECITABINE + OXALIPLATIN | 100081160 |
| 20218747 | 20134986 | 1.7 | 62.8 | Neo-adjuvant (N) | 2019-09-15 | 2019-09-15 | Cabazitaxel | 02 | Y | BORTEZOMIB | 100372477 |
| 20219423 | 20134989 | null | null | Palliative (P) | 2019-07-05 | 2019-07-06 | Cisplatin + Docetaxel +Fluorouracil | 02 | N | IBRUTINIB | 100262703 |
| 20219714 | 20134990 | 1.75 | 115.6 | Neo-adjuvant (N) | 2015-06-28 | 2017-12-06 | SOTORASIB | 1 | null | DARATUMUMAB | 100321831 |
| 20219725 | 20134991 | 1.72 | 69.1 | null | 2021-02-16 | 2021-02-19 | CEMIPLIMAB | 02 | N | RITUXIMAB | 100434847 |
| 20219987 | 20134992 | 1.81 | 67.7 | Curative (C) | 2017-11-29 | 2017-11-29 | Docetaxel + nintedanib | 01 | N | RIPRETINIB | 100518188 |
| 20220087 | 20134993 | 1.81 | 59.8 | Palliative (P) | 2016-02-21 | 2016-02-24 | FCiSt | 02 | N | CAPECITABINE + CETUXIMAB + OXALIPLATIN | 100619517 |
| 20220308 | 20134994 | 1.79 | 94.5 | Palliative (P) | 2021-06-12 | 2021-10-19 | CNS ATRT VCA Vinc/Dactino/Cyclophos + GCSF | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100517890 |
| 20220476 | 20134997 | 1.75 | 72.4 | Palliative (P) | 2019-12-11 | 2019-12-25 | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 02 | N | SCOPE2 TRIAL | 100986042 |
| 20220479 | 20134998 | 1.8 | 74.7 | Neo-adjuvant (N) | 2018-01-17 | 2018-01-17 | Bevacizumab + Oxaliplatin +MdG | 02 | N | GEMCITABINE + PACLITAXEL | 100467656 |
| 20220576 | 20134999 | 1.79 | 25.5 | null | 2017-06-11 | 2017-06-15 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | BEVACIZUMAB + OXALIPLATIN + MdG | 100401732 |
| 20220796 | 20135001 | 1.56 | 28.6 | Palliative (P) | 2016-05-06 | 2016-11-12 | Hydroxycarbamide | 02 | N | CARBO + FLUOROURACIL | 100424166 |
| 20220850 | 20135002 | 1.77 | 76.34 | Neo-adjuvant (N) | 2019-06-21 | 2019-06-23 | Hydroxycarbamide | 2 | null | SCOPE2 TRIAL | 101458418 |
| 20221152 | 20135003 | 1.78 | 80.9 | Adjuvant (A) | 2018-02-08 | 2018-02-22 | Fulvestrant + Palbociclib | 02 | N | CETUXIMAB + IRINOTECAN | 101478129 |
| 20221836 | 20135005 | 1.81 | 68 | null | 2017-01-17 | 2017-03-26 | ECarboX | 02 | null | NAB-PACLITAXEL | 101338877 |
| 20221863 | 20135006 | 1.56 | null | Palliative (P) | 2019-06-19 | 2019-07-09 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | N | BORTEZOMIB | 101074111 |
| 20222527 | 20135007 | 1.21 | 55 | Adjuvant (A) | 2019-12-28 | 2020-01-18 | EOF | null | N | CYCLOPHOSPHAMIDE | 100265649 |
| 20222590 | 20135008 | 1.81 | 51.4 | Palliative (P) | 2018-06-16 | 2018-06-19 | Capecitabine + Streptozocin | 02 | null | CISPLATIN + GEMCITABINE + RITUXIMAB | 100330547 |
| 20223133 | 20135009 | 1.65 | 73.7 | Palliative (P) | 2019-07-24 | 2019-08-14 | Liposomal Doxorubicin (Caelyx) | 02 | N | BACILLUS CALMETTE-GUERIN | 100084661 |
| 20224209 | 20135010 | 1.58 | 53.3 | Palliative (P) | 2019-05-24 | 2019-06-05 | IBRUTINIB | 02 | Y | ACTICCA-1 TRIAL | 100945641 |
| 20224260 | 20135011 | 1.8 | 77.1 | null | 2020-06-03 | 2020-06-04 | CHOP R - 21 days | 02 | N | IRINOTECAN + MDG + PANITUMUMAB | 101152026 |
| 20224380 | 20135012 | 0 | 55.25 | null | 2016-11-06 | 2017-04-28 | BEAM | 01 | null | RITUXIMAB | 100406326 |
| 20224442 | 20135013 | 1.54 | 71 | Neo-adjuvant (N) | 2018-08-08 | 2018-08-10 | CHOP R | N | N | DARATUMUMAB | 101312033 |
| 20224447 | 20135014 | 1.65 | 87 | null | 2020-03-11 | 2020-04-02 | Rucaparib | 01 | null | TOPOTECAN | 101077473 |
| 20224729 | 20135015 | 1.56 | 79 | Palliative (P) | 2019-04-05 | 2019-04-13 | MIC | 02 | N | HYDROXYCARBAMIDE | 101570767 |
| 20224829 | 20135016 | 1.71 | 100.85 | Palliative (P) | 2018-12-17 | 2018-12-30 | FCiSt | 02 | N | EXEMESTANE + PALBOCICLIB | 100465200 |